retatrutide pronunciation in english Obesity doctor warning about retatrutide

The OR for achieving a weight loss of at least 5% with tirzepatide 5 mg, 10 mg and 15 mg (vs GLP-1 RAs) was, respectively, 1.96 (95% CI 1.01, 3.80 [ I 2 61%]), 4.79 (95% CI 1.95, 11.73 [ I 2 74%]) and 4.57 (95% CI 3.38, 6.18 [ I 2 0%]) (ESM Table 2)

At that point, continuing the same medication at higher doses becomes costly and ineffective

The fastest-growing beauty signal is being commercially misread by shelves still organized around aspiration

2024 Oct 22;16(21):3585

Renoprotective effects of GLP-1 receptor agonists: clinical trials The first clinical evidence for beneficial effects of GLP-1 receptor agonists came from the cardiovascular outcome trials (CVOTs) that were conducted with these agents, where kidney endpoints were collected as secondary or exploratory endpoints